{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:20:38Z","timestamp":1789618838792,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ejpb.2019.09.011","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T11:25:58Z","timestamp":1568373958000},"page":"101-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK"],"prefix":"10.1016","volume":"144","author":[{"given":"Rajith K.R.","family":"Rajoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Flexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Chiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan F.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eneko","family":"Larra\u00f1eta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Siccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejpb.2019.09.011_b0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12981-016-0091-1","article-title":"Combination of long-acting HIV fusion inhibitor albuvirtide and LPV\/r showed potent efficacy in HIV-1 patients","volume":"13","author":"Zhang","year":"2016","journal-title":"AIDS Res. Therapy"},{"issue":"3","key":"10.1016\/j.ejpb.2019.09.011_b0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/13548506.2014.945601","article-title":"A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy","volume":"20","author":"Claborn","year":"2015","journal-title":"Psychol., Health Med."},{"issue":"1","key":"10.1016\/j.ejpb.2019.09.011_b0015","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/COH.0000000000000219","article-title":"The promise and pitfalls of long-acting injectable agents for HIV prevention","volume":"11","author":"Landovitz","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"4","key":"10.1016\/j.ejpb.2019.09.011_b0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/COH.0000000000000168","article-title":"Formulation and pharmacology of long-acting cabotegravir","volume":"10","author":"Trezza","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"2","key":"10.1016\/j.ejpb.2019.09.011_b0025","first-page":"182","article-title":"Treatment and prevention: closer to the threshold","volume":"5","author":"Barnhart","year":"2017","journal-title":"Global Health: Sci. Pract."},{"issue":"32","key":"10.1016\/j.ejpb.2019.09.011_b0030","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1016\/j.vaccine.2012.05.011","article-title":"Survey of the prevalence of immunization non-compliance due to needle fears in children and adults","volume":"30","author":"Taddio","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.ejpb.2019.09.011_b0035","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s10461-016-1370-5","article-title":"Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S","volume":"20","author":"Parsons","year":"2016","journal-title":"AIDS Behav."},{"issue":"11","key":"10.1016\/j.ejpb.2019.09.011_b0040","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2217\/nnm.12.214","article-title":"Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients","volume":"8","author":"Williams","year":"2013","journal-title":"Nanomedicine"},{"issue":"12","key":"10.1016\/j.ejpb.2019.09.011_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114700","article-title":"High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: A P18 Cohort Substudy","volume":"9","author":"Meyers","year":"2014","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.ejpb.2019.09.011_b0050","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.drudis.2017.10.013","article-title":"Microarray patches: potentially useful delivery systems for long-acting nanosuspensions","volume":"23","author":"Donnelly","year":"2018","journal-title":"Drug Discovery Today"},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2019.09.011_b0055","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijpharm.2017.02.011","article-title":"Successful application of large microneedle patches by human volunteers","volume":"521","author":"Ripolin","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"23","key":"10.1016\/j.ejpb.2019.09.011_b0060","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1002\/adfm.201200864","article-title":"Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery","volume":"22","author":"Donnelly","year":"2012","journal-title":"Adv. Funct. Mater."},{"issue":"3","key":"10.1016\/j.ejpb.2019.09.011_b0065","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/pharmaceutics7030090","article-title":"Transdermal delivery of drugs with microneedles\u2014potential and challenges","volume":"7","author":"Ita","year":"2015","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejpb.2019.09.011_b0070","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41467-017-02603-z","article-title":"Long-acting injectable atovaquone nanomedicines for malaria prophylaxis","volume":"9","author":"Bakshi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2019.09.011_b0075","article-title":"Towards a maraviroc long-acting injectable nanoformulation","author":"Tatham","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.ejpb.2019.09.011_b0080","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.sna.2006.11.022","article-title":"Laser fabrication of high aspect ratio thin holes on biodegradable polymer and its application to a microneedle","volume":"139","author":"Aoyagi","year":"2007","journal-title":"Sens. Actuators, A"},{"issue":"11","key":"10.1016\/j.ejpb.2019.09.011_b0085","doi-asserted-by":"crossref","first-page":"8952","DOI":"10.1016\/j.actbio.2013.06.029","article-title":"Dissolving polymer microneedle patches for rapid and efficient transdermal delivery of insulin to diabetic rats","volume":"9","author":"Ling","year":"2013","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.ejpb.2019.09.011_b0090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2009.01.025","article-title":"Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB\/c mice","volume":"136","author":"Ding","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2019.09.011_b0095","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/nbt.1504","article-title":"Transdermal drug delivery","volume":"26","author":"Prausnitz","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.ejpb.2019.09.011_b0100","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.biomaterials.2011.09.074","article-title":"Hydrogel swelling as a trigger to release biodegradable polymer microneedles in skin","volume":"33","author":"Kim","year":"2012","journal-title":"Biomaterials"},{"issue":"15","key":"10.1016\/j.ejpb.2019.09.011_b0105","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1073\/pnas.1601653113","article-title":"Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery","volume":"113","author":"Yang","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2019.09.011_b0110","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/s41467-017-01764-1","article-title":"Microneedle-array patches loaded with dual mineralized protein\/peptide particles for type 2 diabetes therapy","volume":"8","author":"Chen","year":"2017","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ejpb.2019.09.011_b0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40262-017-0557-x","article-title":"In silico dose prediction for long-acting rilpivirine and cabotegravir administration to children and adolescents","volume":"57","author":"Rajoli","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.ejpb.2019.09.011_b0120","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/cpt.622","article-title":"Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: frequent utilization in the field of oncology","volume":"101","author":"Yoshida","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ejpb.2019.09.011_b0125","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40262-014-0227-1","article-title":"Physiologically based pharmacokinetic modelling to inform development of intramuscular long-acting nanoformulations for HIV","volume":"54","author":"Rajoli","year":"2015","journal-title":"Clin. Pharmacokinet."},{"issue":"10","key":"10.1016\/j.ejpb.2019.09.011_b0130","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2165\/00003088-200342100-00002","article-title":"Whole body pharmacokinetic models","volume":"42","author":"Nestorov","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.ejpb.2019.09.011_b0135","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijpharm.2012.05.069","article-title":"Influence of skin model on in vitro performance of drug-loaded soluble microneedle arrays","volume":"434","author":"Garland","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2019.09.011_b0140","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/srt.12082","article-title":"Comparison of the stratum corneum thickness measured in vivo with confocal Raman spectroscopy and confocal reflectance microscopy","volume":"20","author":"B\u00f6hling","year":"2014","journal-title":"Skin Res. Technol."},{"issue":"6","key":"10.1016\/j.ejpb.2019.09.011_b0145","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/00015550310015419","article-title":"Epidermal thickness at different body sites: Relationship to age, gender, pigmentation, blood content, skin type and smoking habits","volume":"83","author":"Sandby-Moller","year":"2003","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1016\/j.ejpb.2019.09.011_b0150","unstructured":"Ronald A. Bergman, A.K.A. Paul, M. Heidger Jr., Atlas of Microscopic Anatomy - A Functional Approach, 2nd ed. W B Saunders Co, 1999."},{"issue":"6","key":"10.1016\/j.ejpb.2019.09.011_b0155","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/jps.23106","article-title":"Dermal clearance model for epidermal bioavailability calculations","volume":"101","author":"Ibrahim","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2019.09.011_b0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.toxlet.2014.03.013","article-title":"Application of physiologically-based toxicokinetic modelling in oral-to-dermal extrapolation of threshold doses of cosmetic ingredients","volume":"227","author":"Gajewska","year":"2014","journal-title":"Toxicol. Lett."},{"issue":"8","key":"10.1016\/j.ejpb.2019.09.011_b0165","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1023\/A:1015892621261","article-title":"Predicting fraction dose absorbed in humans using a macroscopic mass balance approach","volume":"8","author":"Sinko","year":"1991","journal-title":"Pharm. Res."},{"issue":"9","key":"10.1016\/j.ejpb.2019.09.011_b0170","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3109\/10408444.2012.709225","article-title":"An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry","volume":"42","author":"Bosgra","year":"2012","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.ejpb.2019.09.011_b0175","doi-asserted-by":"crossref","unstructured":"L.R. Williams, Reference values for total blood volume and cardiac output in humans, 1994. Available from: http:\/\/web.ornl.gov\/info\/reports\/1994\/3445606042010.pdf. Accessed: 18\/01\/2018.","DOI":"10.2172\/10186900"},{"issue":"4","key":"10.1016\/j.ejpb.2019.09.011_b0180","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200847040-00004","article-title":"Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis","volume":"47","author":"Peters","year":"2008","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.ejpb.2019.09.011_b0185","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jps.10005","article-title":"Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution","volume":"91","author":"Poulin","year":"2002","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2019.09.011_b0190","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.01529-09","article-title":"Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation","volume":"54","author":"Klooster","year":"2010","journal-title":"Antimicrobial Agents Chemotherapy"},{"issue":"10101","key":"10.1016\/j.ejpb.2019.09.011_b0195","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2019.09.011_b0200","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2014.02.007","article-title":"Design and physicochemical characterisation of novel dissolving polymeric microneedle arrays for transdermal delivery of high dose, low molecular weight drugs","volume":"180","author":"McCrudden","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2019.09.011_b0205","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jconrel.2017.07.032","article-title":"Transdermal delivery of gentamicin using dissolving microneedle arrays for potential treatment of neonatal sepsis","volume":"265","author":"Gonz\u00e1lez-V\u00e1zquez","year":"2017","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.ejpb.2019.09.011_b0210","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/mame.201500016","article-title":"Microwave-assisted preparation of hydrogel-forming microneedle arrays for transdermal drug delivery applications","volume":"300","author":"Larra\u00f1eta","year":"2015","journal-title":"Macromol. Mater. Eng."},{"key":"10.1016\/j.ejpb.2019.09.011_b0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2017.04.022","article-title":"In vivo studies investigating biodistribution of nanoparticle-encapsulated rhodamine B delivered via dissolving microneedles","volume":"265","author":"Kennedy","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2019.09.011_b0220","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejpb.2017.04.029","article-title":"Repeat application of microneedles does not alter skin appearance or barrier function and causes no measurable disturbance of serum biomarkers of infection, inflammation or immunity in mice in vivo","volume":"117","author":"Vicente-Perez","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"10","key":"10.1016\/j.ejpb.2019.09.011_b0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111547","article-title":"Hydrogel-Forming Microneedles Prepared from \u201cSuper Swelling\u201d Polymers Combined with Lyophilised Wafers for Transdermal Drug Delivery","volume":"9","author":"Donnelly","year":"2014","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.ejpb.2019.09.011_b0230","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijpharm.2014.01.041","article-title":"Layer-by-layer nanoencapsulation of camptothecin with improved activity","volume":"465","author":"Parekh","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.09.011_b0235","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd1304","article-title":"Current status and future potential of transdermal drug delivery","volume":"3","author":"Prausnitz","year":"2004","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"7","key":"10.1016\/j.ejpb.2019.09.011_b0240","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/jps.23155","article-title":"Prediction of concentration & time profile and its inter-individual variability following the dermal drug absorption","volume":"101","author":"Polak","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2019.09.011_b0245","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijpharm.2011.02.023","article-title":"Mathematical models of skin permeability: An overview","volume":"418","author":"Mitragotri","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2019.09.011_b0250","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0168-3659(99)00038-3","article-title":"Analysis of skin disposition of flurbiprofen after topical application in hairless rats","volume":"62","author":"Sugibayashi","year":"1999","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ejpb.2019.09.011_b0255","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1773-2247(14)50041-X","article-title":"Transdermal drug delivery: progress and challenges","volume":"24","author":"Ita","year":"2014","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"5","key":"10.1016\/j.ejpb.2019.09.011_b0260","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10928-013-9328-y","article-title":"A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines","volume":"40","author":"Tegenge","year":"2013","journal-title":"J. Pharmacokinet Pharmacodyn."},{"key":"10.1016\/j.ejpb.2019.09.011_b0265","unstructured":"Clinical Pharmacology and Biopharmaceutics Review(s). Application number: 202022Orig1s000. Center for Drug Evaluation and Research, 2011. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202022Orig1s000ClinPharmR.pdf. Accessed: 17\/07\/2018."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119305454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119305454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:35:48Z","timestamp":1760546148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641119305454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":53,"alternative-id":["S0939641119305454"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.09.011","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}